1. Signaling Pathways
  2. Epigenetics
  3. Small Interfering RNA (siRNA)

Small Interfering RNA (siRNA)

Small Interfering RNA (siRNA) is a small exogenous double-stranded RNA (dsRNA) (20-25 nucleotides), which triggers the RNA interference (RNAi) pathway. The short dsRNA unwinds and the sense strand is degraded. Antisense strand forms RNA induced silencing complex (RISC) with various protein components. The antisense strand retained in RISC is specifically complementary to the target gene mRNA. Meanwhile, RISC has nuclease activity, which can cut and degrade the target gene mRNA, and inhibit the expression of target gene. Incomplete complementarity results in mRNA translation inhibition.

Small Interfering RNA (siRNA) Related Products (37):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-132591
    Inclisiran
    98.10%
    Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research.
    Inclisiran
  • HY-132610
    Givosiran
    Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels. Givosiran can be used for the research of acute intermittent porphyria.
    Givosiran
  • HY-132588
    Lumasiran
    Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1).
    Lumasiran
  • HY-132609
    Patisiran sodium
    Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis.
    Patisiran sodium
  • HY-150150
    SiRNA Negative Control
    SiRNA Negative Control is a siRNA of 21 nucleotides, and can be used as a negative control.
    SiRNA Negative Control
  • HY-147425A
    Zerlasiran sodium
    Inhibitor
    Zerlasiran sodium is an apolipoprotein A (ApoA) synthesis reducer.
    Zerlasiran sodium
  • HY-147266A
    Elebsiran
    Inhibitor
    Elebsiran is a siRNA against hepatitis B and D virus infections .
    Elebsiran
  • HY-132590A
    Revusiran sodium
    Inhibitor
    Revusiran sodium is a 1st-generation short interfering RNA, which directed against transthyretin (TTR) mRNA. Revusiran sodium can be used for transthyretin (TTR)-mediated amyloidosis research.
    Revusiran sodium
  • HY-132589
    Vutrisiran
    Vutrisiran (ALN-TTRsc02) is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran can be used for transthyretin (TTR)-mediated amyloidosis research.
    Vutrisiran
  • HY-145720
    Cemdisiran
    Cemdisiran is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the research of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein.
    Cemdisiran
  • HY-150223
    GalNAc unconjugated/naked Inclisiran
    GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA (siRNA) without GalNAc conjugation. GalNAc unconjugated/naked Inclisiran inhibits the transcription of PCSK-9, and can be used for hyperlipidemia and cardiovascular disease (CVD) research.
    GalNAc unconjugated/naked Inclisiran
  • HY-153609
    AS-Patisiran sodium
    AS-Patisiran sodium is an antisense strand of Patisiran. Patisiran is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran can be used for the research of hereditary TTR amyloidosis.
    AS-Patisiran sodium
  • HY-132596
    Tivanisiran
    Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1).
    Tivanisiran
  • HY-132587
    Fitusiran
    Fitusiran (ALN-AT3SC), an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia.
    Fitusiran
  • HY-147266
    Elebsiran sodium
    Elebsiran sodium is a siRNA against hepatitis B and D virus infections .
    Elebsiran sodium
  • HY-132604
    Fazirsiran
    Fazirsiran (ARO-AAT) is a second-generation RNAi agent. Fazirsiran consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes. Fazirsiran can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.
    Fazirsiran
  • HY-132595
    Teprasiran
    Teprasiran (QPI-1002) is a small interfering RNA that temporarily inhibits p53-mediated cell death that underlies acute kidney injury (AKI).
    Teprasiran
  • HY-150224
    GalNAc unconjugated/naked Fitusiran sodium
    GalNAc unconjugated/naked Fitusiran (sodium), an small interfering RNA without GalNAc conjugation, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia.
    GalNAc unconjugated/naked Fitusiran sodium
  • HY-132606
    Nedosiran
    Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate.
    Nedosiran
  • HY-147425
    Zerlasiran
    Zerlasiran is an apolipoprotein A (ApoA) synthesis reducer.
    Zerlasiran